علاج سرطان المسالك البولية العلوية (الكارسينوما اليوروثيلية) المتقدم أو النقيلي المؤهل لإنفورتيوماب فيدوتين مع بيمبروليزوماب

References

• Offer EV +P as first-line treatment to patients with advanced/metastatic disease.
• This study showed significant improvements in both progression-free survival and OS, with a response rate of 68% for EV + P.
• Offer erdafitinib as an alternative subsequent-line therapy to patients: Previously treated with platinum-containing chemotherapy; Who had disease progression during or after treatment with a PD-1 or PD-L1 inhibitor; Who harbour FGFR DNA genomic alterations (FGFR2/3 mutations or FGFR3 fusions).
• Only offer vinflunine as a second-line treatment to patients with metastatic disease if immunotherapy or combination chemotherapy is not feasible.

DOI: 10.1016/j.eururo.2025.02.023